Hematuria and risk for end-stage kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 3, 2013, Pages 325-330

  Vivante, Asaf ^a,b   Calderon Margalit, Ronit ^c   Skorecki, Karl ^d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Alport syndrome; CKD; Hematuria; IgA nephropathy; TBMD

Indexed keywords

COLLAGEN TYPE 4;

ACUTE KIDNEY FAILURE; ALPORT SYNDROME; CAPILLARY PRESSURE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHROCYTE; EXERCISE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; LEUKOCYTURIA; LIFE EXPECTANCY; MENSTRUATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; RISK; SEXUAL BEHAVIOR; THIN BASEMENT MEMBRANE DISEASE; URINE SEDIMENT;

ACUTE KIDNEY INJURY; AGE FACTORS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS, IGA; HEMATURIA; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHRITIS, HEREDITARY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84878854459     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835f7241     Document Type: Review

References (37)

1. Cohen RA, Brown RS. Microscopic hematuria. N Engl J Med 2003; 348:2330-2338.
2. Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. J Am Med Assoc 2011; 306:729-736.
3. Brown RS. Has the time come to include urine dipstick testing in screening asymptomatic young adults? J Am Med Assoc 2011; 306:764-765.
4. Kovacević Z, Jovanović D, Rabrenović V, et al. Asymptomatic microscopic haematuria in young males. Int J Clin Pract 2008; 62:406-412.
5. Lee YM, Baek SY, Kim JH, et al. Analysis of renal biopsies performed in children with abnormal findings in urinary mass screening. Acta Paediatr 2006; 95:849-853.
6. Park YH, Choi JY, Chung HS, et al. Hematuria and proteinuria in a mass school urine screening test. Pediatr Nephrol 2005; 20:1126-1130.
7. Chow KM, Kwan BC, Li PK, Szeto CC. Asymptomatic isolated microscopic haematuria: long-term follow-up. Q J Med 2004; 97:739-745.
8. Nieuwhof C, Doorenbos C, Grave W, et al. A prospective study of the natural history of idiopathic nonproteinuric hematuria. Kidney Int 1996; 49:222-225.
9. Topham PS, Harper SJ, Furness PN, et al. Glomerular disease as a cause of isolated microscopic haematuria. Q J Med 1994; 87:329-335.
10. Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007; 18:3004-3016.
11. Temme J, Peters F, Lange K, et al. Incidence of renal falure and nephroprotection by RAAS inhibition in heterozygous carriers of X chromosomal and autosomal recessive Alport mutations. Kidney Int 2012; 81:779-783.
12. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738-748.
13. Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22:752-761.
14. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 2012; 7:e38904.
15. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactosedeficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012; 23:1579-1587.
16. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546-556.
17. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534-545.
18. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77:921-927.
19. Kim TY, Kim SB, Park SK. The efficacy of steroid pulse therapy in patients with IgA nephropathy. Clin Nephrol 2012; 78:100-105.
20. Nakagawa N, Kabara M, Matsuki M, et al. Retrospective comparison of the efficacy of tonsillectomy with and without steroid-pulse therapy in IgA nephropathy patients. Intern Med 2012; 51:1323-1328.
21. Ochi A, Moriyama T, Takei T, et al. Comparison between steroid pulse therapy alone and in combination with tonsillectomy for IgA nephropathy. Int Urol Nephrol 2012. [Epub ahead of print]
22. Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol 2012; 16:883-891.
23. Lv J, Xu D, Perkovic V, Ma X, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 2012; 23:1108-1116.
24. Shima Y, Nakanishi K, Hama T, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 2013; 28:71-76.
25. Gutiérrez E, Zamora I, Ballarín JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012; 23:1753-1760.
26. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543-2556.
27. Kashtan CE. Chapter 14: Alport syndrome and thin basement membrane nephropathy. In: Geary DF, Schaefer F, editors. Comprehensive pediatric nephrology, 1st ed. Philadelphia, PA, USA: Mosby, Elsevier; 2008. pp. 229-237.
28. Gross O, Licht C, Anders HJ. Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 2012; 81:494-501.
29. Kashtan CE, Ding J, Gregory M, et al. Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 2013; 28:5-11.
30. Szeto CC, Mac-Moune Lai F, Kwan BC, et al. The width of the basement membrane does not influence clinical presentation or outcome of thin glomerular basement membrane disease with persistent hematuria. Kidney Int 2010; 78:1041-1046.
31. Zurawski J, Salwa-Zurawska W, Woźniak A, et al. Clinical and morphological aspects of thin glomerular basement membrane disease. Pol J Pathol 2009; 60:35-42.
32. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43:321-327.
33. Voskarides K, Arsali M, Athanasiou Y, et al. Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria. Pediatr Nephrol 2012; 27:675-679.
34. Moreno JA, Martín-Cleary C, Gutiérrez E, et al. Haematuria: the forgotten CKD factor? Nephrol Dial Transplant 2012; 27:28-34.
35. Moreno JA, Martín-Cleary C, Gutiérrez E, et al. AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 2012; 7:175-184.
36. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80:181-189.
37. Ware K, Brodsky P, Satoskar AA, et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation. J Am Soc Nephrol 2011; 22:1856-1862.